All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Paradigm Biopharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Paradigm Biopharmaceuticals has Significant Clarity on Development Pathway for Zilusol

Contact the Supplier

Lead Product(s): Pentosan Polysulfate Sodium

Therapeutic Area: Musculoskeletal

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Bell Potter Securities

Deal Size: $35.0 million Upfront Cash: Undisclosed

Deal Type: Financing April 20, 2020

Details:

Proceeds will be applied to costs of the second phase 3 osteoarthritis (OA) clinical trial and leaves Paradigm fully-funded through to completion of this trial.